Results 91 to 100 of about 1,457,300 (387)
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
Molecular Oncology, EarlyView.p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
Immunology of COVID-19: Current State of the Science
Immunity, 2020 Nicolas Vabret +30 more
semanticscholar +1 more source
6th European Congress of Immunology, 1-4 September 2021, Virtual meeting.
European Journal of Immunology, 2021 J. Schulte-Schrepping +131 more
semanticscholar +1 more source
FEBS Open Bio, EarlyView.Skin biopsies taken from a patient with an ultra‐rare disorder as well as controls were cultured for up to 473 days. The chunks of skin were serially transferred to a new culture plate when confluent with fibroblasts. Different generations of fibroblasts were analyzed for cell and molecular properties, proliferation, and competence for reprogramming to
Sudiksha Rathan‐Kumar +3 more
wiley +1 more source
Immunology and immunotherapy of the infections caused byPythium insidiosum [PDF]
, 2005 Leonel Mendoza, Joseph C. Newton
openalex +1 more source